Background Sabin strains used in oral poliovirus vaccines (OPV) can revert to virulence and,
in rare instances, cause disease or generate vaccine-derived strains leading to outbreaks in …

Novel oral poliovirus vaccine type 2 (nOPV2) is being developed to reduce the rare
occurrence of disease and outbreaks associated with the genetic instability of the Sabin …

Background Novel oral poliovirus vaccine type 2 (nOPV2) has been engineered to improve
the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emergence of …

Background Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …

The Sabin oral polio vaccine (OPV) has been remarkably successful, with three major
regions of the world declared polio free. Mutations of the live attenuated poliovirus during …

Background Mass campaigns with oral poliovirus vaccine (OPV) have brought the world
close to the eradication of wild poliovirus. However, to complete eradication, OPV must itself …

For the final stages in the eradication of poliovirus type 1 (P1), the World Health
Organization advocates the selective use of monovalent type 1 oral poliovirus vaccine …

Abstract Background. The production of Sabin inactivated poliovirus vaccine (IPV) can
reduce biosafety requirements in the posteradication/post–oral poliovirus vaccine (OPV) era …

Background Continued emergence and spread of circulating vaccine-derived type 2
polioviruses and vaccine-associated paralytic poliomyelitis from Sabin oral poliovirus …

Abstract (See the article by Nathanson et al., on pages 889–90.) Wild poliovirus has
remained endemic in northern Nigeria because of low coverage achieved in the routine …